Research
https://spark.adobe.com/page/FVoDi7bsWDe4c/
Research Interest 1
For most of the connective tissue diseases, there is currently no effective proven therapy. Development of efficient technologies for the identification and genetic manipulation of the central cell type(s) that are involved in matrix deposition and degradation is a definite step in development of targeted therapeutic modalities in such diseases.
My group focuses on two aspects: 1. Fibrotic diseases where excess deposition of matrix lead to loss of function and 2. Osteoarthritis, where there is increased degradation of matrix leading to failure of cartilage function.
Research groups
Research grants
Genetic approaches for repair & correction of disease associated therapy in Alkaptonuria
THE ALKAPTONURIA SOCIETY (UK)
December 2022 - November 2026
Innovative Approaches to Regulation of Homogentisic Acid and Tyrosine in Alkaptonuria
THE ALKAPTONURIA SOCIETY (UK)
December 2020 - November 2022
The role of circadian rhythms in Collagen VI related Myopathies
MUSCULAR DYSTROPHY UK - MDUK (UK)
July 2022 - November 2024
Abdulrahman Gremida / 201496381 (bench fees)
LIBYAN EMBASSY IN LONDON🚩
April 2020 - March 2024
Bench fee Majed Alghamdi / 201484626
ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)
February 2021 - September 2024
Bench fees for Miss Fawziah Mohammed A Asiri 201459736
ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)
October 2020 - September 2024
Metabolomic consequences of silencing the HGD gene
ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)
November 2019 - November 2023
MOHAMED HASSAN A ALHASHMI - Bench Fees
ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)
July 2018 - September 2022
Sara Ibrahim AlSalhi 201369309 bench fees
ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)
March 2020 - February 2024
Development and pre-clinical evaluation of innovative, multi-disciplinary approaches to target the accumulation of specific amino acids for the treatment of inherited rare diseases with unmet need
BRITISH ACADEMY (UK)
February 2022 - March 2022
Circadian disruption and fibrosis progression in Systemic Sclerosis: towards chrono-based prognostic biomarkers and therapeutic stratification
THE TERESA ROSENBAUM GOLDEN CHARITABLE TRUST (THE ROSETREES TRUST) (UK)
December 2022 - September 2026
UK-Israel Lectureship Scheme
BRITISH COUNCIL (UK)
January 2018 - May 2018
Effects of APPA on ochronosis
AKL RESEARCH & DEVELOPMENT LTD (UK)
November 2016 - January 2018
The role of Syndecan 3 in bone metabolism
MEDICAL RESEARCH COUNCIL
January 2018 - September 2021
Shedding of the endocytic receptor LRP1 in cartilage: A novel link to the development of osteoarthritis.
ARTHRITIS RESEARCH UK
June 2017 - June 2022
Unravelling the molecular mechanism of CCN2 in glaucoma
FIGHT FOR SIGHT (UK)
October 2016 - September 2019
INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN HuR IN MUSCULOSKELETAL DEVELOPMENT AND DISEASE
MEDICAL RESEARCH COUNCIL
July 2016 - December 2019
Defining the mechanisms by which CTGF protects joints from injury -induced osteoarthritis
ARTHRITIS RESEARCH UK
October 2015 - December 2018
Elucidating the pathways regulating venous identity
BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL
July 2014 - June 2017
Validating ADAMTS-4/5 as targets for therapy in a naturally occuring mouse model of osteoarthritis
ARTHRITIS RESEARCH UK
September 2013 - April 2017
The role of Cux1 in scarring and fibrosis in scleroderma
RAYNAUD'S & SCLERODERMA ASSOCIATION (UK)
September 2013 - December 2014
Transcriptional regulation of the Notch and Vegf signalling pathways during angiogenesis and arterio-venous differentiation
MEDICAL RESEARCH COUNCIL
September 2013 - September 2015
Understanding the regulation of the gene critical for the stuctural and functional activity of Cartilage.
THE TERESA ROSENBAUM GOLDEN CHARITABLE TRUST (THE ROSETREES TRUST) (UK)
December 2013 - November 2016
Engineering ligamentous/ tendon tissue for rotator cuff repair.
MEDICAL RESEARCH COUNCIL
November 2014 - March 2018